Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute promyelocytic leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    84 result(s) found for: Acute promyelocytic leukemia. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2005-005397-74 Sponsor Protocol Number: P050604 Start Date*: 2009-04-20
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A randomized trial assessing the role of arsenic trioxide and or ATRA during consolidation course in newly diagnosed acute promyelocytic leukemia (APL)
    Medical condition: Leucémies Aigues Promyélocytaires.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001019 Leucémies Aigues Promyélocytaires PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001151-68 Sponsor Protocol Number: TUD-APOLLO-064 Start Date*: 2016-05-19
    Sponsor Name:Technische Universität Dresden
    Full Title: A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracyclines-based chemotherapy (AIDA regimen) for patients with newly diag...
    Medical condition: newly diagnosed high-risk acute promyelocytic leukemia (APL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001019 Acute promyelocytic leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) NL (Prematurely Ended) BE (Completed) ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-002311-40 Sponsor Protocol Number: ICCAPLStudy01 Start Date*: 2009-07-16
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: TREATMENT STUDY FOR CHILDREN AND ADOLESCENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA
    Medical condition: Patients with a clinical diagnosis of initial APL and subsequently confirmed to have PML-RARα, NPM1-RARα or NUMA-RARα fusion.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001020 Acute promyelocytic leukemia LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002183-99 Sponsor Protocol Number: INNO-507-P2 Start Date*: 2007-09-28
    Sponsor Name:INNOVIVE Pharmaceuticals
    Full Title: Un estudio de fase II de tamibaroteno en pacientes con leucemia promielocítica aguda que hayan recibido terapia previa con ATRA y trióxido de arsénico (STAR-1)
    Medical condition: Pacientes adultos con recidiva de leucemia promielocítica aguda (LPA) o leucemia promielocítica aguda refractaria después de haber sido tratados con ácido trans retinóico total (ATRA) y trióxido de...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001020 Acute promyelocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006188-22 Sponsor Protocol Number: GIMEMA-DSIL APL0406 Start Date*: 2007-07-10
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed, non high-risk acute pro...
    Medical condition: Non high-risk acute promyelocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001019 Acute promyelocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003103-12 Sponsor Protocol Number: AML-CG2008 Start Date*: 2009-03-10
    Sponsor Name:Hospital of the University of Munich
    Full Title: A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy ...
    Medical condition: Adult patients (≥18 years) with newly-diagnosed acute myeloid leukemia (AML) - except acute promyelocytic leukemia (APL) and t(15;17)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003421-28 Sponsor Protocol Number: TUD-HINKL1-059 Start Date*: 2014-07-10
    Sponsor Name:Technische Universität Dreden
    Full Title: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia
    Medical condition: Newly diagnosed high-risk AML other than acute promyelocytic leukemia, ≥20% blasts
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005321-63 Sponsor Protocol Number: DSC/05/2357/15 Start Date*: 2006-03-13
    Sponsor Name:ITALFARMACO
    Full Title: Multicentre, open label, uncontrolled, pilot, phase II study of oral ITF2357 in subjects with acute myeloid leukemia refractory/resistant and/or not suitable for any alternative therapy
    Medical condition: Acute myeloid leukemia AML (any French-American-British [FAB] type with the exception of M3 subtype, acute promyelocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024291 Leukaemias acute myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006852-37 Sponsor Protocol Number: CPKC412A2301 Start Date*: 2008-07-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III randomized, double-blind study of induction(daunorubicin/cytarabine)and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients <...
    Medical condition: newly diagnosed FLT3 mutated acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) SK (Completed) HU (Completed) BE (Completed) IT (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000526-37 Sponsor Protocol Number: SAIL Start Date*: 2014-08-18
    Sponsor Name:GSO Global Clinical Research B.V.
    Full Title: An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination with the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Relapsed Or Refractory A...
    Medical condition: Patients with relapsed/refractory Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    19.1 100000004864 10000886 Acute myeloid leukemia LLT
    19.1 100000004864 10066638 Acute myeloid leukemia progression LLT
    19.1 100000004864 10028557 Myeloid leukemia, acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001321-68 Sponsor Protocol Number: B1761026 Start Date*: 2018-05-22
    Sponsor Name:Pfizer, Inc.
    Full Title: Gemtuzumab Ozogamicin (mylotarg (registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/refractory Acute Myelogenous Leukemia Who May Benefit From Treatm...
    Medical condition: Acute Myelogenous Leukemia, including myelodysplastic syndrome and acute promyelocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005023-40 Sponsor Protocol Number: RG_11-182 Start Date*: 2013-05-22
    Sponsor Name:University of Birmingham
    Full Title: ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy
    Medical condition: Acute myeloid leukaemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003482-28 Sponsor Protocol Number: SGN33A-005 Start Date*: 2016-07-14
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed ac...
    Medical condition: Acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) BE (Completed) AT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003191-12 Sponsor Protocol Number: TUD-2DAUNO-058 Start Date*: 2014-01-31
    Sponsor Name:Technische Universität Dresden
    Full Title: Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of in-duction therapy for adult patients with acute myeloid leukemia ≤65 years
    Medical condition: Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria, i.e. bone marrow aspirate or biopsy must contain ≥20% blasts of all nucleated cells or differential bloo...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    21.1 100000004864 10066353 Treatment related acute myeloid leukemia LLT
    21.0 100000004864 10000887 Acute myeloid leukemia in remission LLT
    21.0 100000004864 10054294 Acute myeloid leukemia (in remission) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-000404-92 Sponsor Protocol Number: HOVON 92 AML Start Date*: 2008-09-12
    Sponsor Name:HOVON Foundation
    Full Title: Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia...
    Medical condition: AML according to WHO classification (excluding acute promyelocytic leukaemia) or refractory anemia with excess of blasts (RAEB) and IPSS score ≥1.5 or therapy-related AML/RAEB or biphenotypic le...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    9.1 10054593 Refractory anemia with excess blasts in transformation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004440-12 Sponsor Protocol Number: CPKC412A2408 Start Date*: 2017-11-12
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia ...
    Medical condition: newly diagnosed FLT3 mutated acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) CZ (Completed) ES (Ongoing) HU (Completed) FR (Completed) BG (Completed) GR (Completed) SK (Completed) LT (Completed) IT (Completed) EE (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-004427-38 Sponsor Protocol Number: 0001A3-300-GL Start Date*: 2009-01-28
    Sponsor Name:Antisoma Research Ltd.
    Full Title: Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)
    Medical condition: secondary acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing) AT (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002864-36 Sponsor Protocol Number: PKRPC001 Start Date*: 2021-11-04
    Sponsor Name:Priothera S.A.S.
    Full Title: A prospective randomized, double-blind, placebo-controlled, multi-center phase IIb study to evaluate the efficacy and safety of mocravimod in acute myeloid leukemia (AML) patients undergoing alloge...
    Medical condition: Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003210-40 Sponsor Protocol Number: IMGN632-0801 Start Date*: 2019-02-27
    Sponsor Name:IMMUNOGEN, INC.
    Full Title: A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123- positive Acute Myeloid Leukemia and Other CD123 positive Hematologic Malignancies
    Medical condition: CD123 positive Acute Myeloid Leukemia and other CD123 positive hematologic malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001721-29 Sponsor Protocol Number: SPD758-216 Start Date*: 2005-12-05
    Sponsor Name:SGX Pharmaceuticals, Inc.
    Full Title: An Open-Label, Single-Arm, Multi-Center, Phase II/III study of Troxatyl (Troxacitabine) Administered by Continuous Infusion in Patients with Acute Myeloid Leukemia (AML) in second salvage
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 03:38:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA